Memphasys Limited (ASX:MEM) equine fertility study announcement

Australian reproductive biotechnology company Memphasys Limited (ASX:MEM) has announced its commitment to a transformative equine fertility study that will significantly advance the global commercialisation of the Felix™ device, positioning it as the leading technology for equine sperm selection.

Executive Commentary on Equine Fertility Study

Dr David Ali, CEO of Memphasys, stated, 'Strategies such as this are value focused and driving the clinical utility and application of these devices into new areas of new opportunity to bring ROI to our investor base.'

Summary of Memphasys Equine Fertility Study Announcement

Memphasys (ASX:MEM) has committed to a three-year equine fertility study to position the Felix™ device as the leading technology for equine sperm selection. The study, in collaboration with the University of Newcastle and EquiBreedUK Ltd, aims to establish Felix™ as the preferred technology for equine sperm selection, with the goal of enabling its rapid commercialisation post-publication of study results. The global Equine Artificial Insemination (AI) market, valued at USD 681.1 million in 2023, presents a significant opportunity for Memphasys. The study is expected to produce publishable results within 12 months, supporting direct sales of Felix™ in the non-thoroughbred market without the need for major device modification. Memphasys anticipates leveraging over $1 million in research value, significantly enhancing its IP portfolio and positioning Felix™ for rapid market entry at a fraction of the cost of a dedicated clinical trial. With the support of key partners and a clear pathway to market, Memphasys is poised for significant growth in the animal fertility sector.